203 related articles for article (PubMed ID: 23621222)
1. XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy.
Zhang T; Sun J; Lv M; Zhang L; Wang X; Ren JC; Wang B
Asian Pac J Cancer Prev; 2013; 14(2):701-5. PubMed ID: 23621222
[TBL] [Abstract][Full Text] [Related]
2. XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy.
Zou HZ; Zhao YQ
Genet Mol Res; 2015 Jan; 14(1):500-6. PubMed ID: 25729984
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer.
Hu W; Pan J; Zhao P; Yang G; Yang S
Tumour Biol; 2014 Jun; 35(6):5561-7. PubMed ID: 24615519
[TBL] [Abstract][Full Text] [Related]
5. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
[TBL] [Abstract][Full Text] [Related]
6. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
Mlak R; Krawczyk P; Homa-Mlak I; Powrózek T; Ciesielka M; Kozioł P; Milanowski J; Małecka-Massalska T
Pathol Oncol Res; 2019 Jul; 25(3):1035-1045. PubMed ID: 30066234
[TBL] [Abstract][Full Text] [Related]
7. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.
Wang YD; Ha MW; Cheng J; Zhang WL; Cong X; Tong CY; Sun J
Oncol Rep; 2012 Apr; 27(4):979-86. PubMed ID: 22179630
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese.
Xu JL; Hu LM; Huang MD; Zhao W; Yin YM; Hu ZB; Ma HX; Shen HB; Shu YQ
Asian Pac J Cancer Prev; 2012; 13(3):851-6. PubMed ID: 22631660
[TBL] [Abstract][Full Text] [Related]
9. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.
He C; Duan Z; Li P; Xu Q; Yuan Y
Anticancer Drugs; 2013 Mar; 24(3):300-5. PubMed ID: 23211354
[TBL] [Abstract][Full Text] [Related]
10. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Feng J; Sun X; Sun N; Qin S; Li F; Cheng H; Chen B; Cao Y; Ma J; Cheng L; Lu Z; Ji J; Zhou Y
Acta Biochim Biophys Sin (Shanghai); 2009 May; 41(5):429-35. PubMed ID: 19430706
[TBL] [Abstract][Full Text] [Related]
11. Association of
Wang XQ; Terry PD; Li Y; Zhang Y; Kou WJ; Wang MX
World J Gastroenterol; 2019 Sep; 25(34):5152-5161. PubMed ID: 31558863
[TBL] [Abstract][Full Text] [Related]
12. XPG rs2296147 T>C polymorphism predicted clinical outcome in colorectal cancer.
Wang F; Zhang SD; Xu HM; Zhu JH; Hua RX; Xue WQ; Li XZ; Wang TM; He J; Jia WH
Oncotarget; 2016 Mar; 7(10):11724-32. PubMed ID: 26887052
[TBL] [Abstract][Full Text] [Related]
13. An insight into clinical outcome of XPG polymorphisms in breast cancer.
Malik SS; Mubarik S; Masood N; Khadim MT
Mol Biol Rep; 2018 Dec; 45(6):2369-2375. PubMed ID: 30255276
[TBL] [Abstract][Full Text] [Related]
14. XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.
Xiang T; Kang X; Gong Z; Bai W; Chen C; Zhang W
Cancer Chemother Pharmacol; 2017 Apr; 79(4):791-800. PubMed ID: 28314991
[TBL] [Abstract][Full Text] [Related]
15. XPG polymorphisms and their association with lung cancer susceptibility, overall survival and response in North Indian patients treated with platinum-based doublet chemotherapy.
Lawania S; Singh N; Behera D; Sharma S
Future Oncol; 2019 Jan; 15(2):151-165. PubMed ID: 30522358
[TBL] [Abstract][Full Text] [Related]
16. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen.
Li P; Wang YD; Cheng J; Chen JC; Ha MW
Tumour Biol; 2015 Dec; 36(12):9465-73. PubMed ID: 26124006
[TBL] [Abstract][Full Text] [Related]
17. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
Ren S; Zhou S; Zhang L; Xu J; Lv M; Zhang J; Zhou C; Zhang J
Cancer Invest; 2010 Dec; 28(10):1078-83. PubMed ID: 20504223
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.
Krawczyk P; Wojas-Krawczyk K; Mlak R; Kucharczyk T; Biernacka B; Milanowski J
Folia Histochem Cytobiol; 2012 Apr; 50(1):80-6. PubMed ID: 22532140
[TBL] [Abstract][Full Text] [Related]
19. Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.
Chen X; Zhang L; Ren S; Li X; Zhou F; Li W; Gao G; He Y; Zhou C
Med Oncol; 2014 Apr; 31(4):865. PubMed ID: 24535606
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
Liao WY; Shih JY; Chang GC; Cheng YK; Yang JC; Chen YM; Yu CJ
J Thorac Oncol; 2012 Jun; 7(6):973-81. PubMed ID: 22551904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]